Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 46-52

  Akers, Kevin S ^a,b   Rowan, Matthew P ^a   Niece, Krista L ^a   Stewart, Ian J ^b   Mende, Katrin ^b,c   Cota, Jason M ^d   Murray, Clinton K ^b   Chung, Kevin K ^a,e  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c Infectious Diseases Clinical Research Program   (United States)

^d UNIVERSITY OF THE INCARNATE WORD   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; DOXYCYCLINE; LEVOFLOXACIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ACUTE KIDNEY FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW VELOCITY; BURN PATIENT; CASE REPORT; CONTINUOUS HEMOFILTRATION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LENGTH OF STAY; MALARIA CONTROL; MALE; MINIMUM INHIBITORY CONCENTRATION; RHABDOMYOLYSIS; SEPSIS; STEADY STATE; URINE VOLUME; UROLOGICAL THERAPEUTIC DEVICE; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; BLOOD; BURN; BURN UNIT; DRUG EFFECTS; HEMOFILTRATION; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; BURN UNITS; BURNS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEMOFILTRATION; HUMANS; MALE;

EID: 84920137062     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03783-14     Document Type: Article

References (46)

1. Walsh TR, Toleman MA. 2012. The emergence of pan-resistant Gramnegative pathogens merits a rapid global political response. J Antimicrob Chemother 67:1-3. http://dx.doi.org/10.1093/jac/dkr378.
2. Wertheim H, Van Nguyen K, Hara GL, Gelband H, Laxminarayan R, Mouton J, Cars O. 2013. Global survey of polymyxin use: a call for international guidelines. J Glob Antimicrob Resist 1:131-134. http://dx .doi.org/10.1016/j.jgar.2013.03.012.
3. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1953-1958. http://dx.doi.org/10.1128/AAC .00035-06.
4. Zavascki AP. 2014. Polymyxins for the treatment of extensively-drugresistant Gram-negative bacteria: from pharmacokinetics to bedside. Expert Rev Anti Infect Ther 12:531-533. http://dx.doi.org/10.1586 /14787210.2014.902307.
5. Orwa JA, Govaerts C, Busson R, Roets E, Van Schepdael A, Hoogmartens J. 2001. Isolation and structural characterization of colistin components. J Antibiot (Tokyo) 54:595-599. http://dx.doi.org/10.7164 /antibiotics.54.595.
6. Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 59:88-94. http://dx.doi.org/10.1093 /cid/ciu213.
7. Li J, Nation RL, Turnidge JD. 2006. Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother 50:4231. (Reply, 50:4231-4232.) http://dx.doi .org/10.1128/AAC.00756-06.
8. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2014. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis 58:139-141. http://dx.doi.org /10.1093/cid/cit680.
9. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. 1970. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72:857-868. http://dx.doi.org/10.7326/0003-4819-72-6-857.
10. Jamal JA, Mat-Nor MB, Mohamad-Nor FS, Udy AA, Lipman J, Roberts JA. 2014. A national survey of renal replacement therapy prescribing practice for acute kidney injury in Malaysian intensive care units. Nephrology (Carlton) 19:507-512. http://dx.doi.org/10.1111/nep.12276.
11. Legrand M, Darmon M, Joannidis M, Payen D. 2013. Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med 39:101-108. http://dx.doi.org/10.1007/s00134-012-2706-x.
12. Friedrich JO, Wald R, Bagshaw SM, Burns KE, Adhikari NK. 2012. Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis. Crit Care 16:R146. http://dx.doi.org/10 .1186/cc11458.
13. Chung KK, Lundy JB, Matson JR, Renz EM, White CE, King BT, Barillo DJ, Jones JA, Cancio LC, Blackbourne LH, Wolf SE. 2009. Continuous venovenous hemofiltration in severely burned patients with acute kidney injury: a cohort study. Crit Care 13: R62. http://dx .doi.org/10.1186/cc7801.
14. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. 2003. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 47:1364-1370. http://dx.doi.org/10.1128/AAC.47.4 .1364-1370.2003.
15. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. 2001. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in sol-id-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 761:167-175. http: //dx.doi.org/10.1016/S0378-4347(01)00326-7.
16. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 46:3304-3307. http://dx.doi.org/10.1128/AAC.46.10 .3304-3307.2002.
17. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury Network. 2007. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31. http://dx.doi.org/10.1186/cc5713.
18. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294. http://dx.doi.org /10.1128/AAC.01733-10.
19. Colton CK, Henderson LW, Ford CA, Lysaght MJ. 1975. Kinetics of hemodiafiltration. I. In vitro transport characteristics of a hollow-fiber blood ultrafilter. J Lab Clin Med 85:355-371.
20. Henderson LW, Colton CK, Ford CA. 1975. Kinetics of hemodiafiltration. II. Clinical characterization of a new blood cleansing modality. J Lab Clin Med 85:372-391.
21. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 47:1766-1770. http://dx.doi.org/10 .1128/AAC.47.5.1766-1770.2003.
22. Li J, Rayner CR, Nation RL, Deans R, Boots R, Widdecombe N, Douglas A, Lipman J. 2005. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 49:4814-4815. http: //dx.doi.org/10.1128/AAC.49.11.4814-4815.2005.
23. Markantonis SL, Markou N, Fousteri M, Sakellaridis N, Karatzas S, Alamanos I, Dimopoulou E, Baltopoulos G. 2009. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 53:4907-4910. http://dx.doi.org/10.1128/AAC.00345-09.
24. Durmaz R, Otlu B, Koksal F, Hosoglu S, Ozturk R, Ersoy Y, Aktas E, Gursoy NC, Caliskan A. 2009. The optimization of a rapid pulsed-field gel electrophoresis protocol for the typing of Acinetobacter baumannii, Escherichia coli and Klebsiella spp. Jpn J Infect Dis 62:372-377.
25. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233-2239.
26. Karvanen M, Plachouras D, Friberg LE, Paramythiotou E, Papadomichelakis E, Karaiskos I, Tsangaris I, Armaganidis A, Cars O, Giamarellou H. 2013. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 57:668-671. http://dx.doi.org/10.1128 /AAC.00985-12.
27. Strunk AK, Schmidt JJ, Baroke E, Bode-Boger SM, Martens-Lobenhoffer J, Welte T, Kielstein JT. 2014. Single- and multiple-dose pharmacokinetics and total removal of colistin in a patient with acute kidney injury undergoing extended daily dialysis. J Antimicrob Chemother 69:2008-2010. http://dx.doi.org/10.1093/jac/dku075.
28. Bohler J, Donauer J, Keller F. 1999. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int (Suppl):S24-S28.
29. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. 2009. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 37:2268-2282. http://dx.doi.org/10.1097/CCM .0b013e3181aab3d0.
30. Roberts JA, Lipman J. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840-851; quiz, 859. http://dx.doi .org/10.1097/CCM.0b013e3181961bff.
31. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin MH, Le Naour G, Marquette CH, Rouby JJ. 2010. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 36:1147-1155. http://dx.doi .org/10.1007/s00134-010-1879-4.
32. Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, Golmard JL, Rouby JJ, Nebulized Antibiotics Study Group. 2012. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii . Anesthesiology 117:1335-1347. http://dx.doi.org/10.1097/ALN.0b013e31827515de.
33. Claure-Del Granado R, Macedo E, Chertow GM, Soroko S, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL. 2011. Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis. Clin J Am Soc Nephrol 6:467-475. http://dx.doi.org/10.2215/CJN .02500310.
34. Dana AP, Ahmar CA, Clapp WL, Ross EA. 2011. A new form of myeloma "kidney": shortened hemofilter survival and implications for membrane filtration plasmapheresis. Clin Nephrol 75:120-124. http://dx.doi .org/10.5414/CNP75120.
35. Laurent I, Adrie C, Vinsonneau C, Cariou A, Chiche JD, Ohanessian A, Spaulding C, Carli P, Dhainaut JF, Monchi M. 2005. High-volume hemofiltration after out-of-hospital cardiac arrest: a randomized study. J Am Coll Cardiol 46:432-437. http://dx.doi.org/10.1016/j.jacc.2005.04.039.
36. Rimmele T, Kellum JA. 2012. High-volume hemofiltration in the intensive care unit: a blood purification therapy. Anesthesiology 116:1377-1387. http://dx.doi.org/10.1097/ALN.0b013e318256f0c0.
37. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56:4241-4249. http://dx.doi.org/10 .1128/AAC.06426-11.
38. Martyn JA, Abernethy DR, Greenblatt DJ. 1984. Plasma protein binding of drugs after severe burn injury. Clin Pharmacol Ther 35:535-539. http: //dx.doi.org/10.1038/clpt.1984.73.
39. Pos O, van der Stelt ME, Wolbink GJ, Nijsten MW, van der Tempel GL, van Dijk W. 1990. Changes in the serum concentration and the glycosylation of human alpha 1-acid glycoprotein and alpha 1-protease inhibitor in severely burned persons: relation to interleukin-6 levels. Clin Exp Immunol 82:579-582.
40. Azad MA, Huang JX, Cooper MA, Roberts KD, Thompson PE, Nation RL, Li J, Velkov T. 2012. Structure-activity relationships for the binding of polymyxins with human alpha-1-acid glycoprotein. Biochem Pharmacol 84:278-291. http://dx.doi.org/10.1016/j.bcp.2012.05.004.
41. Lee J, Han S, Jeon S, Hong T, Song W, Woo H, Yim DS. 2013. Population pharmacokinetic analysis of colistin in burn patients. Antimicrob Agents Chemother 57:2141-2146. http://dx.doi.org/10.1128/AAC.00271-13.
42. Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, Nation RL. 2010. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 54:1117-1124. http://dx.doi.org/10.1128/AAC.01114-09.
43. Kim Y, Bae IK, Lee H, Jeong SH, Yong D, Lee K. 2014. In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment. Diagn Microbiol Infect Dis 79:362-366. http://dx.doi.org/10.1016/j.diagmicrobio.2014.03.027.
44. Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus-Leone F, Preston L, St Clair K, Nikolich M, Viscount H, Wortmann G, Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman PE. 2013. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis 208:1142-1151. http://dx.doi.org /10.1093/infdis/jit293.
45. Snitkin ES, Zelazny AM, Gupta J, Program NCS, Palmore TN, Murray PR, Segre JA. 2013. Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment. Genome Res 23: 1155-1162. http://dx.doi.org/10.1101/gr.154328.112.
46. Cai Y, Chai D, Wang R, Liang B, Bai N. 2012. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67:1607-1615. http://dx.doi.org/10 .1093/jac/dks084.